Reason for request
Re-assessment of methylphenidate-based proprietary products in attention-deficit hyperactivity disorder in response to a request from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of CONCERTA LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years and over when psychological, educational and social management alone prove insufficient. |
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
DM2uGY3wwz7VDXXg
